Ipsen Signs an Exclusive WW License Agreement with IRLAB for Mesdopetam to Treat Parkinson Disease
Shots:
- IRLAB to receive ~$363M- including $28M as up front and ~$335M as development- regulatory and commercial milestones along with royalties on WW net sales of mesdopetam
- Ipsen get the exclusive WW rights to develop and commercialize mesdopetam (novel dopamine D3-receptor antagonist) which is currently being evaluated in P- IIb clinical trials for patients with PD experiencing LID
- IRLAB will be responsible for the ongoing P-IIb trial while Ipsen will initiate P- III preparatory activities- and is responsible for all remaining clinical development and commercialization globally
Ref: Ipsen | Image: Genetic Engineering and Biotechnology News
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com